Navigation Links
Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments
Date:10/6/2011

type of cancer and predict its severity.

"The problem is, anytime you have a human being in the equation, there's always a question of variability," he said. "What one observer calls aggressive, another may not."

Madabhushi noted that until less than a decade ago, oncologists would be cautious and prescribe both hormone therapy and chemotherapy because the severity was often hard to determine. In 2004, California-based Genomic Health introduced a test that examined gene expression. That test accurately pegged ER+ breast cancers that fell at the low and high ends of the severity scale. Women who scored low could be treated confidently with hormonal therapy alone and forgo chemotherapy.

While the test, known as Oncotype DX, became an important planning resource for oncologists and patients, it remains expensive upwards of $4,000. It also takes two weeks to produce results, which for severe cancers represents a loss of valuable treatment time.

"In 2007, an oncologist at The Cancer Institute of New Jersey, Shridar Ganesan, saw our work on prostate cancer imaging and asked if my lab could apply it to ER-positive breast cancers," said Madabhushi, who is also a member of The Cancer Institute of New Jersey. "So we applied these techniques and started to get very exciting results. We found that our image-based risk score, which we dubbed 'Ibris,' was in agreement with the Oncotype DX score almost 90 percent of the time."

Work funded by the NIH grant, made through the agency's National Institute for Biomedical Imaging and Bioengineering, will establish how well Ibris scores predict long-term patient outcomes. If successful, an Ibris test could deliver results to patients almost immediately and cut costs to patients and their insurers.

The benefits could be even more dramatic in developing countries, claims Madabhushi, where the Oncotype DX cost is prohibitive and sending samples to California can add weeks to the testing
'/>"/>

Contact: Carl Blesch
cblesch@ur.rutgers.edu
732-932-7084 x616
Rutgers University
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
2. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
3. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
4. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
5. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
6. Iowa State chemist synthesizes carbohydrates, launches startup company
7. ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor
8. delSECUR CORPORATION Announces Appointment of the Companys President & CEO
9. Two is not company -- as far as fish are concerned
10. GATC Biotech AG is investing more than 5 million euros in its Constance site to double the companys floor space
11. Company Granted Patent on Apparatus, Systems, and Methods for Gathering and Processing Wireless Biometric and Biomechanical Data
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
... University of British Columbia zoologist has discovered a new ... and one of the earliest vertebrates dating back 500 ... evolution of steroid hormones and may help conservation and ... significant scientific implications and application for lamprey conservation," says ...
... WOODS HOLE, MAWhen searching for long-lost treasure, sometimes all ... "flashlight," developed at the Marine Biological Laboratory,s (MBL) Josephine ... long-neglected cellular component the nucleolinus and confirm ... and Mary Anne Alliegro, and MBL visiting investigator Jonathan ...
Cached Biology News:Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3UBC researcher discovers ancient 'stress hormone' in pre-historic fish 2Rediscovery: MBL scientists confirm role for mysterious cell component, the nucleolinus 2
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Mylan Inc. (Nasdaq: MYL ) today announced that ... $1.25 million to support two prominent West Virginia cultural institutions ... West Virginia and the State of West Virginia Division of ... a member of Mylan Charitable Foundation,s board of directors said ...
... Encorium Group, Inc. (Nasdaq:  ENCO), (the "Company"), a ... studies in over 30 countries for many of ... announced that, on October 20, 2010, it received ... "Panel") has determined to delist the Company,s securities ...
... but it has become even harder in recent years the ... slow it down anymore. Reporting their findings in the journal ... closer to understanding why not, and how future treatments can defeat ... drugs, amantadine and rimantadine, are no longer recommended by the CDC ...
Cached Biology Technology:Mylan and Mylan Charitable Foundation Award a Collective $1.25 Million to Prominent West Virginia Cultural Institutions 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 3Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 4Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2
... a new tuning and calibration standard for ... Accumix is a lyophilized 7-peptide standard ... both tuning and calibration of ion trap ... transform mass spectrometers. Direct infusion of ...
Determin interaction of your protein with Echelons lipids...
... N-Dodecyl-N,N-(dimethylammonio)butyrate White crystalline solid. HYGROSCOPIC. ... DDMAU (Cat. No. 252005) but differing in ... efficient for the extraction of mycoplasma membrane ... Purity: ≥98% by TLC. Soluble in ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Biology Products: